Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo. | Arch Biochem Biophys | 2025 | 39581340 | PubTator, text mining | PubMed |
| One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors. | Eur J Med Chem | 2025 | 39488968 | PubTator, text mining | PubMed |
| Wuzi Yanzong Decoction Ameliorates Oligoasthenozoospermia by Up-Regulating Methyltransferase and Increasing Spata, Bcl, and Pik3 Series Genes Methylation Level. | Chem Biodivers | 2025 | 39441614 | PubTator, text mining | PubMed |
| PRMT5 Maintains Tumor Stem Cells to Promote Pediatric High-Grade Glioma Tumorigenesis. | Mol Cancer Res | 2025 | 39422546 | PubTator, text mining | PubMed |
| A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma. | Mol Cancer Ther | 2025 | 39387112 | PubTator, text mining | PubMed |
| AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. | Cancer Discov | 2025 | 39282709 | PubTator, text mining | PubMed |
| Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. | Mol Oncol | 2025 | 39021294 | PubTator, text mining | PubMed |
| Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. | bioRxiv | 2025 | 38826355 | PubTator, text mining | PubMed |
| [Expressions of PRMT5 and DKK3 proteins in prostate cancer tissue correlate to biochemical recurrence after radical prostatectomy]. | Zhonghua Nan Ke Xue | 2024 | 40783916 | PubTator, text mining | PubMed |
| Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia. | Curr Pharmacol Rep | 2024 | 40756330 | PubTator, text mining | PubMed |
Molecular Characterization and Potential Inhibitors Prediction of Protein Arginine Methyltransferase-2 in Carcinoma: An Insight from Molecular Docking, ADMET Profiling and Molecular Dynamics Simulation Studies. | Euroasian J Hepatogastroenterol | 2024 | 39802857 | PubTator, text mining | PubMed |
| Inhibitory Effect of PRMT5/MTA Inhibitor on MTAP-Deficient Glioma May Be Influenced by Surrounding Normal Cells. | Cancer Med | 2024 | 39711357 | PubTator, text mining | PubMed |
| A review of the known MTA-cooperative PRMT5 inhibitors. | RSC Adv | 2024 | 39691229 | PubTator, text mining | PubMed |
| A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer. | Front Oncol | 2024 | 39678513 | PubTator, text mining | PubMed |
| Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs. | Front Oncol | 2024 | 39655075 | PubTator, text mining | PubMed |
| Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. | Signal Transduct Target Ther | 2024 | 39627201 | PubTator, text mining | PubMed |
| MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Induces Cell Cycle Arrest and Synergizes With Oxaliplatin and Gemcitabine for Enhanced Anticancer Effects. | Anticancer Res | 2024 | 39626906 | PubTator, text mining | PubMed |
| Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer. | J Exp Clin Cancer Res | 2024 | 39614393 | PubTator, text mining | PubMed |
| PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis. | Cancers (Basel) | 2024 | 39594744 | PubTator, text mining | PubMed |
| Role of PRMT5 mediated HOXA10 arginine 337 methylation in endometrial epithelial cell receptivity. | Biochem Biophys Res Commun | 2024 | 39550865 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=19